Soliris
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Soliris in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Soliris.
49
Global Revenue Ranking
Recent articles on PMLiVE featuring Soliris
Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US
The drug has been recommended for use alongside the company’s C5 inhibitors
Paroxysmal nocturnal haemoglobinuria affects approximately 1.59 per 100,000 people in the UK
The drug is now the first monthly subcutaneous treatment authorised for use in this patient population
Epysqli has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
More than 6,500 new cases of the blood cancer were diagnosed in the US last year
The company is planning to file for US approval of the CD19-targeted drug in this patient population
Bkemv has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors
Up to 20% of patients treated with C5 inhibitors experience clinically significant extravascular haemolysis
Up to 20% of PNH patients treated with a C5 inhibitor experience clinically significant extravascular haemolysis
The programme already faces court challenges from drugmakers and industry groups
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology